https://www.investing.com/news/pro/talc-plaintiffs-will-press-to-reopen-litigation-against-johnson--johnson-432SI-3037108

AdvaMed, the world''s leading medical technology association, announced that Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, was elected Chairman of the AdvaMed Board of Directors for a two-year term beginning today. McEvoy has served on the AdvaMed Board of Directors since 2018. She has led important initiatives for the Association, including overseeing AdvaMed efforts to expand and strengthen global market access for U.S. medtech firms thro… Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=302456

Award-Winning Coach Cheryl Mann to Join Team SACRAMENTO, CA / ACCESSWIRE / March 22, 2023 / In a groundbreaking move to counter the negative effects of COVID-19 on the workforce environment and to navigate burnout and difficulty returning to the work world, Star Staffing, a leading Northern California-based firm enlisted the expert council of performance coach Cheryl Mann. Mann is a team development expert with over 20 years of experience who empowers leaders and teams to reach their fullest potential, including AT&T, Johnson & Johnson, PG&E, Kaiser Permanente, and Sutter Health. "We''ve been through so much trauma over these past few years, and we''re all facing stress and burnout," says Star Staffing President Nicole Smartt Serres. "It seems we''re all feeling emotions more intensely - especially fear. I don''t want that for our employees." Looking for a proactive solution, Serres considered how athletes, entrepreneurs, and elite professionals use performance coaches to help them achieve their goals.

Johnson & Johnson (NYSE:JNJ) is currently trading at a decade-low forward P/E ratio. This is particularly interesting since the healthcare behemoth…

SAN DIEGO, CA / ACCESSWIRE / March 21, 2023 / Rancho Biosciences, a leading data sciences services company, is pleased to announce that Regeneron has become the latest Member to join its Single Cell Data Science (SCDS) pre-competitive consortium, along with existing Members: BenevolentAI, Bristol Myers Squibb, Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis and Vesalius Therapeutics. The mission of the SCDS consortium is to find a common industry standard around how single cell datasets are created and formatted by a systematic effort to develop data models and ensure that public data are curated in a consistent way. Due to the undeniable impact of single cell transcriptomics technology on drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods by pharmaceutical companies. The availability of ever-increasing amounts of single cell datasets in the public domain allows pharmaceutical companies to dramatically expand their universe of single cell experiments over those generated internally.

10 Employers Receive Company''s First-Ever Tech Transformer Distinction: Amtrak, Chevron, Fidelity Investments, General Motors, Hilton, The Home Depot, Johnson & Johnson, JP Morgan Chase & Co, The National Security Agency, and The New York Times SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / Today, Handshake , the largest Gen Z career network, announced its inaugural " Tech Transformer " list highlighting 10 employers who are taking innovative approaches to recruit the next generation of tech talent. Amidst the volatility and hiring slowdown in the tech industry, Handshake is launching this list as part of a broader effort to highlight the many ways to launch a career in tech. This year''s Tech Transformers represent a range of industries outside of the tech sector itself that have a growing need for tech talent and are using Handshake to find it. Handshake Early Talent Awards: Tech Transformers "The tech dream job is shifting in real-time for the class of 2023 as they head toward graduation," said Garrett Lord, Co-Founder and CEO of Handshake. "We want to help students on Handshake see that there are many ways to launch a successful and high-impact career in tech, from working in robotics at Johnson & Johnson to building electric vehicles at General Motors." The Tech Transformer distinction is a new addition to Handshake''s Early Talent Awards (ETAs) , an annual list the company announced today of employers recognized for best-in-class early talent engagement.

Revenues rise by 9.5 per cent to €1.04 billion

WHY: New York, NY - (NewMediaWire) - March 19, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023. SO WHAT: If you purchased Fate securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fate class action, go to https://rosenlegal.com/submit-form/?case_id=11392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Close to its 52-week low, this healthcare stalwart remains a good purchase.

Johnson & Johnson''s (NYSE: JNJ ) short percent of float has risen 32.35% since its last report. The company recently reported that it has 11.72 million shares sold short , which is 0.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of … Full story available on Benzinga.com

Benzinga takes a look back at a notable market-related moment that occurred on this date. What Happened? On this day in 1997, Walmart Inc (NYSE: WMT ), Johnson & Johnson (NYSE: JNJ ), Travelers Companies Inc (NYSE: TRV ) and Hewlett Packard Enterprise Co (NYSE: HPE ) joined the Dow Jones Industrial Average. Where The Market Was: The S&P 500 traded at 795.71 and the Dow traded at 6,955.48. What Else Was Going On In The World? In 1997, Princess Diana was killed in a car … Full story available on Benzinga.com

Additional post-hoc analysis of TREMFYA showed improvements in scalp psoriasis and quality-of-life measures at week 48 SPRING HOUSE, Pa. , March 17, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA ® (guselkumab) was associated with greater treatment persistence a compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patients b living with moderate to severe plaque psoriasis (PsO), based on pairwise analyses c of real-world data. 1,2 Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scalp PsO. 3 TREMFYA is the first and only fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque PsO. 4 These study results are among 14 company-sponsored abstracts being presented by Janssen at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, LA .

SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE ) investors who suffered significant losses to submit your losses now . Class Period: Apr. 2, 2020 – Jan. 5, 2023 Lead Plaintiff Deadline: Mar. 22, 2023 Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: FATE@hbsslaw.com 844-916-0895 Fate Therapeutics, Inc. (FATE) Securities Fraud Class Action: The litigation focuses on Fate''s widely touted April 2020 collaboration agreement with Janssen Biotech, pursuant to which Janssen and Fate agreed to collaborate to develop iPSC-derived CAR-NK and CAR T-cell product candidates for the treatment of cancer. Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties. According to the complaint, Defendants made materially misleading statements and failed to disclose that: (1) the Janssen agreement was … Full story available on Benzinga.

Around November, the ICMR sought the drug regulator''s nod for phase-3 trials of a vaccine candidate it developed with drugmakers SII and Panacea Biotec

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide in polycythemia vera, achieving its primary endpoint of proportion of responders on rusfertide versus placebo (p=0.0003) NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "The positive FRONTIER 1 JNJ-2113 (PN-235) data recently reported represents a scientific breakthrough with the potential to transform the treatment landscape for moderate-to-severe plaque psoriasis with oral targeted therapy. We look forward to in-depth presentations of JNJ-2113 pre-clinical and Phase 1 and Phase 2 clinical studies at medical conferences beginning in the second quarter of 2023," said Dinesh V.

After favorable peer-reviewed preclinical data for its dengue antiviral JNJ-1802, Johnson & Johnson (JNJ) is advancing the oral therapy into mid-stage studies. Read the full story here.

DUBLIN , March 15, 2023 /PRNewswire/ -- The "Generic Pharmaceuticals Global Market Report 2023" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global generic pharmaceuticals market is expected to grow from $302.39 billion in 2021 to $332.43 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The generic pharmaceuticals market is expected to reach $426.30 billion in 2026 at a CAGR of 6.4%. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war''s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth.

High uncertainty may continue to loom over the stock market, but that doesn’t mean you need to stay on the sidelines. Instead, keep your eyes on the long-term, with solid additions to your portfolio, such as the best blue-chip stocks to buy and hold. These high-quality names have historically provided investors with solid total returns. First, through steady dividend payouts that grow over time. Most of these top blue-chips are “dividend aristocrats,” with over 25 years of consecutive dividend growth. Some of them are even “dividend kings,” with dividend growth track records spanning 50 years or more. Second, along with these dividends, these types of stocks gradually appreciate in value over time. You may not get rich quickly with them, but over an extended timeframe, you have the opportunity to build wealth. So, what are the best blue-chip stocks to buy and hold for the coming decades? Consider these seven, all of which are safe harbors in the near-term, solid winners for your portfolio in the long-term.

The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans Findings support further clinical development for prevention and treatment of dengue, which impacts mil…

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and tre

Johnson & Johnson (NYSE:NYSE:JNJ) Barclays Global Healthcare Conference March 14, 2023 10:15 AM ETCompany ParticipantsAldo Denti - Company Group Chairman, DePuy Synthes The Orthopedic…

Canada''s main stock index hit a two-month low on Monday, with banks and energy stocks leading declines, as global investors turned away from riskier assets on worries about the abrupt shutdown of Silicon Valley Bank (SVB). The TSX came off its lows of the morning, but still trailed breakeven by 60.74 points, to reach noon hour EDT Monday at 19,714.18. Daylight Saving Time kicked in throughout much of North America on the weekend. The Canadian dollar stormed ahead 0.47 cents to 73.09 cents U.S. A Canadian banking regulator on Sunday said it was taking temporary control of the beleaguered bank''s unit in the country. The TSX has shed most of its year-to-date gains on the back of recent underperformance in banks and commodity-linked stocks. The index is now up just 1% so far this year. ON BAYSTREET The TSX Venture Exchange was negative 1.54 points to 609.05. The 12 TSX subgroups were evenly divided between gainers and losers, as energy tumbled 1.9%, financials were down 1.4%, and consumer discretionary stocks faltered 1.1%.

The Forced Medication of All Citizens Authored by Karen Hunt via Off-Guardian.org, “…most men and women will grow up to love their servitude and will never dream of revolution.” - Aldous Huxley, Brave New World It all started back in the 1950s with “these drugs will make you feel better, just try them .” And people did. Over the years it morphed into “ WE RECOMMEND these drugs if you don’t want to be sick, depressed or dead.” Almost everyone listened and accepted that drugs were the answer and there was no way to live without them. Over the past three years it’s been “YOU MUST TAKE these drugs or else you endanger your own life and the lives of those around you.” By this point, people were so conditioned to take drugs that they thought nothing of submitting to an experimental mRNA gene therapy that the experts promised would keep them “safe”. Within the next couple of years, it will be “ YOU ARE REQUIRED to take these drugs by law and if you don’t, you will go to prison for endangering the planet.” Having been consistently brainwashed for all these years, most people will unquestioningly comply.

The concept of buy and hold may seem out of fashion given the state of the market in 2023. But if the threat of higher interest rates hasn’t sent you to the sidelines, blue-chip stocks offer an opportunity to get a total return that can beat inflation. Today, we’ll look at seven of the best blue-chip stocks to buy this month. Blue-chip stocks are defined as companies that have reliable business models and a history of delivering long-term total returns for shareholders. One characteristic that helps blue-chip stocks deliver solid total returns is a safe and growing dividend. This gives you a reliable source of income whether the stock price is up or down. In a raging bull market fueled by effectively 0% interest rates and quantitative easing, it’s hardly a stock picker’s market. But when the market begins to correct, it’s a different story. That’s when investors must be more selective. And when investors look for quality in bear markets, blue-chip stocks like the ones below rise to the top.

SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ: FATE ) investors who suffered significant losses to submit your losses now . Class Period: Apr. 2, 2020 – Jan. 5, 2023 Lead Plaintiff Deadline: Mar. 22, 2023 Visit: https://www.hbsslaw.com/investor-fraud/FATE Contact An Attorney Now: FATE@hbsslaw.com 844-916-0895 Fate Therapeutics, Inc. (FATE) Securities Fraud Class Action: The litigation focuses on Fate''s widely touted April 2020 collaboration agreement with Janssen Biotech, pursuant to which Janssen and Fate agreed to collaborate to develop iPSC-derived CAR-NK and CAR T-cell product candidates for the treatment of cancer. Under this agreement, Fate received a $50 million up front payment and was eligible to receive up to $3 billion in various milestone payments and royalties. According to the complaint, Defendants made materially misleading statements and failed to disclose that: (1) the Janssen … Full story available on Benzinga.

SVB Financial (NASDAQ: SIVB ) stock is currently under a trading halt on Friday as investors await pending news from the company. That trading halt went into effect at 8:35 a.m. today with a T1 code . The T1 code means the halt was introduced “pending the release of material news.” What that news is still isn’t known as the halt remains in place as of this writing. However, we do know that SVB Financial has experienced a massive fall these last couple of days. This follows the company’s announcement of a proposed public stock offering to raise additional funds. Following that announcement, shares of SIVB stock underwent a massive 60% drop in trading on Thursday. That triggered investors and companies to pull their funds from the company, and also sparked a series of downgrades for the stock. SIVB Stock Movement Today Before the trading halt went into effect, shares of SIVB stock were among the biggest losers in our pre-market coverage. That’s despite company CEO Greg Becker attempting to soothe upset investors in a call yesterday.

Source: Alexander Tolstykh / Shutterstock.com Johnson & Johnson (NYSE: JNJ ) layoffs are on the way as the medical, pharmaceutical, and consumer goods company cuts jobs. These layoffs have Johnson & Johnson cutting 350 jobs at its Auris Health and Verb Surgical robotic surgery businesses. The majority of these cuts come from Auris Health, which is reducing its headcount by 292 workers. Johnson & Johnson entered the robotic surgery space in 2019 but hasn’t achieved the results it hoped for. That’s weighing on the company as it spent $3.4 billion to acquire Auris Health at that time. Johnson & Johnson CFO Joe Wolk talked about the problem in an investor call earlier this week. Here’s what he said, as recorded by MedTechDive . “We have to get better with the soft tissue robot Ottava. Our board is actually going out to visit that platform later this year. While we’re behind and while we certainly want to do better, we have a sense of urgency. We realize it’s very early in this game. So, about 5% of surgeries globally are done with robotic platforms.” Johnson & Johnson Joins Layoffs Trend Investors will note that Johnson & Johnson is far from the only company announcing layoffs recently.

Johnson & Johnson''s business model is as defensive as they come. Click here to read on two superior low-volatility SWAN alternatives to JNJ stock.

WILMINGTON, DE / ACCESSWIRE / March 10, 2023 / Extensive adoption of guide catheters in percutaneous coronary intervention has created significant revenue opportunities for medical device companies in the global Percutaneous Coronary Intervention Guidance Devices Market . Increase in R&D of coronary guidewires and catheters is likely to improve patient outcomes and broaden the market outlook. The market value is projected to exceed US$ 23.5 Bn by the end of 2031. Rise in prevalence of coronary artery disease, especially in the elderly, is fueling technological advancements in guidewires and catheters. New catheter designs and novel stenting technologies are being utilized in PCI, leading to better surgical outcomes in patients with chronic symptomatic coronary artery disease. For instance, utilization of bioresorbable scaffolds is expected to increase in percutaneous coronary interventions. Medtech companies in the percutaneous coronary intervention guidance devices industry strive to develop and commercialize vascular closure devices that can reduce complications in PCI procedures especially among patients with a significant risk profile.

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Famotidine tablets indicated for the treatment of acid indigestion and heartburn. The approval granted by the US Food & Drugs Administration (USFDA) for the abbreviated new drug application (ANDA) of Famotidine tablets is for strengths of 10 mg and 20 mg for over-the-counter (OTC) use, Marksans Pharma said in a regulatory filing. The product is bioequivalent to the reference-listed drug (RLD), Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc which has sales of over USD 200 million in the US market, it added. "We are delighted to continue OTC gastro portfolio expansion for our customers and it will help us to fulfill an important therapy gap created in the Antacids market due to Ranitidine withdrawal," Marksans Pharma Managing Director Mark Saldanha said. The company''s OTC Famotidine tablets are acid reducers, used to treat …

Kellogg, Johnson & Johnson, Crane, and BorgWarner are planning to hive off a chunk of their businesses in 2023. What investors need to know.

Johnson & Johnson with ticker code (JNJ) now have 20 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 215 and 161 and has a mean target at 181.75. Now with the previous closing price of 154.09 this would imply there is a potential upside of 18.0%. The 50 day moving average now sits at 165.94 and the 200 moving average now moves to 170.3. The company has a market cap of $398,352m. Visit the company website at: https://www.jnj.com [stock_market_widget type="chart" template="basic" color="green" assets="JNJ" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $469,859m based on the market concensus. Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company''s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON''S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Companies Profiled in the Intrathecal Pumps Market Are Tricumed Medizintechnik GmbH ,Medallion Therapeutics, Inc., Johnson & Johnson Services, Inc., Medtronic, Teleflex Incorporated, FLOWONIX MEDICAL INC. Companies Profiled in the Intrathecal Pumps Market Are Tricumed Medizintechnik GmbH ,Medallion Therapeutics, Inc., Johnson & Johnson Services, Inc., Medtronic, Teleflex Incorporated, FLOWONIX MEDICAL INC.

Kenvue Inc., a wholly owned subsidiary of Johnson & Johnson (JNJ) has priced $7.75B of senior unsecured notes in a series of eight tranches.The notes offering comprised as follows: $750M…

Fed Chair Jerome Powell confirmed in his testimony to Congress Tuesday and Wednesday the Federal Reserve is prepared to raise interest rates above 5% to combat inflation . As a result, the two-year treasury yield has reached a 15-year-high, hitting nearly 5% Wednesday. This means that you can buy virtually risk-free bonds that will give you an annual payout of 5% return on invested capital. In a macro environment where stock returns are uncertain, these T-bills become more attractive to investors. It’s important to note that your return on dividend stocks will also be dependent on the performance of the stock, whereas the T-bills are virtually guaranteed to pay you out the yield advertised. The current two-year bonds will give you a higher yield than these major dividend players: Johnson & Johnson (NYSE: Full story available on Benzinga.com

Although public companies that suffer staggering losses often do so for good reason, sometimes, it might be worthwhile to take a shot with stocks at 52-week lows. Some of the justification comes down to the mechanics of contrarianism. Essentially, traders who shorted troubled securities need to exit their positions. For the bears, this exiting necessitates buying back borrowed shares, thus sparking bullish momentum. In other cases, certain enterprises may be overlooked and/or undervalued. With so many people having access to the internet these days, it’s rarer to find truly overlooked opportunities. Nevertheless, the number of publicly available securities also increased, meaning that some organizations invariably won’t get the attention they deserve. So, if you’re ready to gamble with the speculation side of your portfolio, these are the stocks at 52-week lows. GO Grocery Outlet $26.70 JNJ Johnson & Johnson $152.92 PFE Pfizer $40.12 SIRI Sirius XM $3.86 SBNY Signature Bank $103.09 GEN Gen Digital $18.37 BAK Braskem $8.03 Grocery Outlet (GO) Source: Shutterstock An American discount closeout retailer consisting exclusively of supermarket locations that offer deeply discounted, overstocked, and closeout products from name brand and private label suppliers, Grocery Outlet (NASDAQ: GO ) fundamentally offers much relevance.

Kenvue, the consumer health spinoff of health care giant Johnson & Johnson (JNJ), has begun an 8-part bond sale to fund its separation, Bloomberg reported.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmac…

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, ma

Johnson & Johnson (NYSE:NYSE:JNJ) Cowen 43rd Annual HealthCare Conference March 7, 2023 11:10 AM ETCompany ParticipantsJoe Wolk - EVP and CFOJessica Moore - VP, IRConference Call…

Protagonist Therapeutics (PTGX) announced Tuesday that plaque psoriasis candidate JNJ-2113, developed with Johnson & Johnson succeeded in a Phase 2 trial. Read the full story here.

Although the topic of climate change generates intense debate, its growing reality dictates that investors consider modifying their portfolios to target certain stocks to buy. As NASA’s website states, “[t]here is unequivocal evidence that Earth is warming at an unprecedented rate. Further, human activity represents the principal catalyst . Fortunately, several public enterprises have stepped up to the plate, ready to deliver tangible solutions. A major component of the underlying proposals centers on environmental, social, and governance ( ESG ) initiatives. To be sure, mentioning ESG can spark political disagreements. However, because younger generations tend to be progressive about sustainability concerns, targeting stocks to buy based on climate change-related matters may be astute. After all, they represent the future. Finally, with overwhelming consensus among scientists that climate change represents a genuine phenomenon, the trend is clear. With that, these are the stocks to buy amid the environmental crisis.

The Janssen Pharmaceutical Companies of Johnson & Johnson <> announces results from the Phase 3 A DUE study, which showed an investigational once-daily, single tablet…

Selling the May 155 call option generates an income of 3.42% in just over two months, equaling around 17% annualized.

Findings presented at ACC.23 show XARELTO ® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo LER are four times more likely to experience acute limb ischemia, which can lead to amputation or death if left untreated 1 XARELTO ® is the first and only anticoagulant approved in combination with aspirin for reducing the risk of major thrombotic vascular events * in patients with peripheral artery disease (PAD) TITUSVILLE, N.J. , March 5, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO ® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD.

New data on Johnson & Johnson''s Stelara (ustekinumab) showed that the IL-12 and IL-23 antagonist demonstrated long-term durable efficacy and safety in Crohn''s disease.

Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years SPRING HOUSE, Pa. , March 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab) through five years in adults with moderately to severely active Crohn''s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC. 1,2 These data are a part of Janssen''s 22 oral and poster presentations at the 18 th Congress of the European Crohn''s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark , March 1-4 . "These data reinforce the known efficacy and safety profile of STELARA, and demonstrate it can be an effective long-term treatment option for patients living with moderately to severely active ulcerative colitis," said UNIFI study author Waqqas Afif , M.D., Associate Professor, Department of Medicine, Division of Experimental Medicine and Division of Gastroenterology at McGill University Health Centre in Montreal, Canada . a "Importantly, clinical and endoscopic outcomes reinforce the durable efficacy of STELARA, as we remain committed to developing therapies that provide patients with lasting remission." Final STELARA long-term pooled safety analysis (Oral presentation OP39): 1 A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up.

Johnson & Johnson stock is now trading at 15 times earnings, due to renewed legal concerns. Click here to read my analysis of JNJ stock.

Bristol Myers Squibb (BMY) in collaboration with Janssen Pharmaceuticals, a Johnson and Johnson (JNJ) company announces the launch of Phase 3 Librexia program studying milvexian,…